A carregar...
Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma
Cabozantinib was recently approved for the treatment of advanced renal cell carcinoma (RCC) after treatment with vascular endothelial growth factor (VEGF)‐targeted therapy. Cabozantinib is a multikinase inhibitor targeting VEGF receptor (VEGFR) 2, mesenchymal‐epithelial transition receptor, and “ane...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905684/ https://ncbi.nlm.nih.gov/pubmed/29146618 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0335 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|